MATHEMATICAL-MODEL FOR INVIVO PHARMACODYNAMICS INTEGRATING FLUCTUATION OF THE RESPONSE - APPLICATION TO THE PROLACTIN SUPPRESSANT EFFECT OF THE DOPAMINOMIMETIC DRUG DCN 203-922

被引:15
作者
FRANCHETEAU, P
STEIMER, JL
DUBRAY, C
LAVENE, D
机构
[1] SANDOZ PHARMA,DRUG SAFETY ASSESSMENT PHARMACOMETRY,CH-4002 BASEL,SWITZERLAND
[2] INSERM,DEPT BIOMATH,U 194,91 BLVD HOP,F-75634 PARIS 13,FRANCE
[3] LABS SANDOZ,CTR RECH PRECLIN,F-92506 RUEIL MALMAISON,FRANCE
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1991年 / 19卷 / 03期
关键词
PHARMACOKINETIC-PHARMACODYNAMIC MODEL; CIRCADIAN VARIATION; PLACEBO; HORMONE; DOPAMINOMIMETIC DRUG; PROLACTIN; DCN; 203-922; SPLINE SMOOTHING; SIMULATION;
D O I
10.1007/BF03036252
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We propose a general pharmacokinetic-pharmacodynamic model that integrates the rhythmic fluctuation of hormone secretion for the description of the hormone-lowering effect of a drug. The mathematical model takes into account the variation in response observed after administration of a placebo and the drug. It is assumed that the change with time in the physiological response during the placebo period results from fluctuations in the concentration of hypothetical endogenous molecules. The mathematical formulation for predicting the response after drug intake is derived assuming competitive interaction of these "molecules" with the active species for binding to receptors. The suggested "fluctuation model" was implemented in order to describe the time course of the prolactin (PRL) plasma level after administration of two oral doses (2.5 and 5.0 mg) of the dopaminomimetic compound DCN 203-922 (DCN) to 9 healthy male subjects. Its performance was compared with that of conventional modeling approaches,in which the circadian changes after placebo are neglected and the hormone baseline is assumed to be constant. The new model provided a better description of the time course of PRL in most subjects. It was used for prediction of the amplitude and duration of the PRL suppressant effect after single and chronic administration of DCN at various dosage regimens as well as after changes in drug absorption.
引用
收藏
页码:287 / 309
页数:23
相关论文
共 28 条
  • [1] Boor CD., 1978, PRACTICAL GUIDE SPLI
  • [2] VERAPAMIL PHARMACODYNAMICS AFTER INTRAVENOUS AND ORAL DOSING - THEORETIC CONSIDERATION
    COLBURN, WA
    BRAZZELL, RK
    HOLAZO, AA
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (01) : 71 - 73
  • [3] COLBURN WA, 1988, PHARMACOKINETICS PHA, V2, P167
  • [4] METABOLIC-CLEARANCE AND PRODUCTION-RATES OF PROLACTIN IN MAN
    COOPER, DS
    RIDGWAY, EC
    KLIMAN, B
    KJELLBERG, RN
    MALOOF, F
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1979, 64 (06) : 1669 - 1680
  • [5] A NON-GAUSSIAN MODEL FOR TIME-SERIES WITH PULSES
    DIGGLE, PJ
    ZEGER, SL
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1989, 84 (406) : 354 - 359
  • [6] FRANTZ AG, 1979, ENDOCRINE RHYTHMS, P175
  • [7] A SYSTEM APPROACH TO PHARMACODYNAMICS .2. GLYBURIDE PHARMACODYNAMICS AND ESTIMATION OF OPTIMAL DRUG DELIVERY
    GILLESPIE, WR
    VENGPEDERSEN, P
    ANTAL, EJ
    PHILLIPS, JP
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1988, 77 (01) : 48 - 55
  • [8] GREVEL J, 1986, BRIT J CLIN PHARMACO, V22, P1
  • [9] UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS
    HOLFORD, NHG
    SHEINER, LB
    [J]. CLINICAL PHARMACOKINETICS, 1981, 6 (06) : 429 - 453
  • [10] KEICHEL JR, 1987, PHARM CLIN ACTUALITI, V156, P91